1 5120 116 POSSIBLE EPIGENETIC REGULATORY EFFECT OF DYSREGULATED CIRCULAR RNAS IN EPILEPSY. CIRCULAR RNAS (CIRCRNAS) INVOLVE IN THE EPIGENETIC REGULATION AND ITS MAJOR MECHANISM IS THE SEQUESTRATION OF THE TARGET MICRO RNAS (MIRNAS). WE HYPOTHESIZED THAT CIRCRNAS MIGHT BE RELATED WITH THE PATHOPHYSIOLOGY OF CHRONIC EPILEPSY AND EVALUATED THE ALTERED CIRCRNA EXPRESSIONS AND THEIR POSSIBLE REGULATORY EFFECTS ON THEIR TARGET MIRNAS AND MRNAS IN A MOUSE EPILEPSY MODEL. THE CIRCRNA EXPRESSION PROFILE IN THE HIPPOCAMPUS OF THE PILOCARPINE MICE WAS ANALYZED AND COMPARED WITH CONTROL. THE CORRELATION BETWEEN THE EXPRESSION OF MIRNA BINDING SITES (MIRNA RESPONSE ELEMENTS, MRE) IN THE DYSREGULATED CIRCRNAS AND THE EXPRESSION OF THEIR TARGET MIRNAS WAS EVALUATED. AS MIRNAS ALSO INHIBIT THEIR TARGET MRNAS, CIRCRNA-MIRNA-MRNA REGULATORY NETWORK, COMPRISED OF DYSREGULATED RNAS THAT TARGETS ONE ANOTHER WERE SEARCHED. FOR THE IDENTIFIED NETWORKS, BIOINFORMATICS ANALYSES WERE PERFORMED. AS THE RESULT, FORTY-THREE CIRCRNAS WERE DYSREGULATED IN THE HIPPOCAMPUS (UP-REGULATED, 26; DOWN-REGULATED, 17). THE CHANGE IN THE EXPRESSION OF MRE IN THOSE CIRCRNAS NEGATIVELY CORRELATED WITH THE CHANGE IN THE RELEVANT TARGET MIRNA EXPRESSION (R = -0.461, P<0.001), SUPPORTING THAT CIRCRNAS INHIBIT THEIR TARGET MIRNA. 333 DYSREGULATED CIRCRNA-MIRNA-MRNA NETWORKS WERE IDENTIFIED. GENE ONTOLOGY AND PATHWAY ANALYSES DEMONSTRATED THAT THE UP-REGULATED MRNAS IN THOSE NETWORKS WERE CLOSELY RELATED TO THE MAJOR PROCESSES IN EPILEPSY. AMONG THEM, STRING ANALYSIS IDENTIFIED 37 KEY MRNAS WITH ABUNDANT (>/=4) INTERACTIONS WITH OTHER DYSREGULATED TARGET MRNAS. THE DYSREGULATION OF THE CIRCRNAS WHICH HAD MULTIPLE INTERACTIONS WITH KEY MRNAS WERE VALIDATED BY PCR. WE CONCLUDED THAT DYSREGULATED CIRCRNAS MIGHT HAVE A PATHOPHYSIOLOGIC ROLE IN CHRONIC EPILEPSY BY REGULATING MULTIPLE DISEASE RELEVANT MRNAS VIA CIRCRNA-MIRNA-MRNA INTERACTIONS. 2018 2 4583 18 N6-METHYLADENINE RNA METHYLATION EPIGENETIC MODIFICATION AND KIDNEY DISEASES. RNA METHYLATION MODIFICATION IS A RAPIDLY DEVELOPING FIELD IN EPIGENETICS. N6-METHYLADENSINE (M(6)A) IS THE MOST COMMON INTERNAL MODIFICATION IN EUKARYOTIC MRNA. M(6)A GROUP REGULATES RNA SPLICING, STABILITY, TRANSLOCATION, AND TRANSLATION. ENZYMES CATALYZING THIS PROCESS WERE TERMED AS WRITERS, ERASERS, AND READERS. RECENT STUDIES HAVE FOCUSED ON EXPLORING THE ROLE OF RNA METHYLATION IN HUMAN DISEASES. RNA METHYLATION MODIFICATIONS, PARTICULARLY M(6)A, PLAY IMPORTANT ROLES IN THE PATHOGENESIS OF KIDNEY DISEASES. IN THIS REVIEW, WE PROVIDE A BRIEF DESCRIPTION OF M(6)A AND SUMMARIZE THE IMPACT OF M(6)A ON ACUTE AND CHRONIC KIDNEY DISEASE (CKD) AND POSSIBLE FUTURE STUDY DIRECTIONS FOR THIS RESEARCH. 2023 3 1336 23 DESCRIBING A TRANSCRIPTION FACTOR DEPENDENT REGULATION OF THE MICRORNA TRANSCRIPTOME. WHILE THE TRANSCRIPTION REGULATION OF PROTEIN CODING GENES WAS EXTENSIVELY STUDIED, LITTLE IS KNOWN ON HOW TRANSCRIPTION FACTORS ARE INVOLVED IN TRANSCRIPTION OF NON-CODING RNAS, SPECIFICALLY OF MICRORNAS. HERE, WE PROPOSE A STRATEGY TO STUDY THE POTENTIAL ROLE OF TRANSCRIPTION FACTOR IN REGULATING TRANSCRIPTION OF MICRORNAS USING PUBLICALLY AVAILABLE DATA, COMPUTATIONAL RESOURCES AND HIGH THROUGHPUT DATA. WE USE THE H3K4ME3 EPIGENETIC SIGNATURE TO IDENTIFY MICRORNA PROMOTERS AND CHROMATIN IMMUNOPRECIPITATION (CHIP)-SEQUENCING DATA FROM THE ENCODE PROJECT TO IDENTIFY MICRORNA PROMOTERS THAT ARE ENRICHED WITH TRANSCRIPTION FACTOR BINDING SITES. BY TRANSFECTING CELLS OF INTEREST WITH SHRNA TARGETING A TRANSCRIPTION FACTOR OF INTEREST AND SUBJECTING THE CELLS TO MICRORNA ARRAY, WE STUDY THE EFFECT OF THIS TRANSCRIPTION FACTOR ON THE MICRORNA TRANSCRIPTOME. AS AN ILLUSTRATIVE EXAMPLE WE USE OUR STUDY ON THE EFFECT OF STAT3 ON THE MICRORNA TRANSCRIPTOME OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS. 2016 4 1568 25 DNA METHYLATION OF TUMOR-SUPPRESSOR MIRNA GENES IN CHRONIC LYMPHOCYTIC LEUKEMIA. DNA METHYLATION IS ONE OF THE MOST IMPORTANT EPIGENETIC MODIFICATIONS OF THE GENOME INVOLVED IN THE REGULATION OF NUMEROUS CELLULAR PROCESSES THROUGH GENE SILENCING WITHOUT ALTERING DNA SEQUENCES. MIRNAS, A CLASS OF SINGLE-STRANDED NONCODING RNAS OF 19-25 NUCLEOTIDES IN LENGTH, FUNCTION AS POST-TRANSCRIPTIONAL REGULATORS OF GENE EXPRESSION LEADING TO MRNA CLEAVAGE OR TRANSLATIONAL REPRESSION OF THEIR CORRESPONDING TARGET PROTEIN-CODING GENES. RECENTLY, DYSREGULATION OF TUMOR SUPPRESSOR MIRNAS MEDIATED BY PROMOTER DNA HYPERMETHYLATION IS IMPLICATED IN HUMAN CANCERS, INCLUDING B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). MOREOVER, IT APPEARS THAT METHYLATED MIRNA GENES COULD BE POTENTIAL BIOMARKERS FOR CLL DIAGNOSIS OR THERAPY. THIS REVIEW WILL HIGHLIGHT THE ROLE OF ABERRANT METHYLATION OF MIRNA GENES IN THE PATHOGENESIS OF CLL. 2015 5 4713 20 NON-CODING RNA AND N6-METHYLADENOSINE MODIFICATION PLAY CRUCIAL ROLES IN NEUROPATHIC PAIN. AFTER PERIPHERAL NERVE INJURY, PAIN SIGNALS ARE TRANSMITTED FROM PRIMARY SENSORY NEURONS IN THE DORSAL ROOT GANGLION (DRG) TO THE CENTRAL NERVOUS SYSTEM. EPIGENETIC MODIFICATION AFFECTS NEUROPATHIC PAIN THROUGH ALTERATIONS IN THE GENE EXPRESSION IN PAIN-RELATED AREAS AND GLIAL CELL ACTIVATION. RECENT STUDIES HAVE SHOWN THAT NON-CODING RNA AND N6-METHYLADENOSINE (M6A) METHYLATION MODIFICATION PLAY PIVOTAL REGULATORY ROLES IN THE OCCURRENCE AND MAINTENANCE OF NEUROPATHIC PAIN. DYSREGULATION OF THE RNA M6A LEVEL VIA DYNAMIC CHANGES IN METHYLTRANSFERASE AND DEMETHYLASE AFTER CENTRAL OR PERIPHERAL NERVE INJURY COMMONLY REGULATES PAIN-ASSOCIATED GENES, CONTRIBUTING TO THE INDUCTION AND MAINTENANCE OF NEUROPATHIC PAIN. THE DYNAMIC PROCESS HAS SIGNIFICANT IMPLICATIONS FOR THE DEVELOPMENT AND MAINTENANCE OF NEUROPATHIC PAIN. HOWEVER, THE UNDERLYING MECHANISMS BY WHICH NON-CODING RNA AND M6A RNA MODIFICATION REGULATE NEUROPATHIC PAIN ARE NOT WELL-CHARACTERIZED. THIS ARTICLE ELUCIDATES THE MULTIPLE MECHANISMS OF NON-CODING RNA AND M6A METHYLATION IN THE CONTEXT OF NEUROPATHIC PAIN, AND SUMMARIZES ITS POTENTIAL FUNCTIONS AS WELL AS RECENT ADVANCES. 2022 6 263 22 ADVANCES WITH LONG NON-CODING RNAS IN DIABETIC PERIPHERAL NEUROPATHY. LONG NON-CODING RNAS (?LNCRNAS) ?ARE A GROUP OF NON-CODING RNAS LONGER THAN 200 NUCLEOTIDES, WHICH ARE DEFINED AS TRANSCRIPTS. THE LNCRNAS ARE INVOLVED IN REGULATING GENE EXPRESSION AT EPIGENETIC, TRANSCRIPTIONAL, AND POST-TRANSCRIPTIONAL LEVELS. RECENT STUDIES HAVE FOUND THAT LNCRNA IS CLOSELY RELATED TO MANY DISEASES LIKE NEUROLOGICAL DISEASES, ENDOCRINE AND METABOLIC DISORDERS. DIABETIC PERIPHERAL NEUROPATHY (DPN) IS ONE OF THE MOST COMMON CHRONIC COMPLICATIONS OF DIABETES MELLITUS. IN THIS REVIEW, WE HIGHLIGHT THE LATEST RESEARCH RELATED TO LNCRNAS IN DPN. 2020 7 1720 27 DYSREGULATED N6-METHYLADENOSINE (M(6)A) PROCESSING IN HEPATOCELLULAR CARCINOMA. N6-METHYLADENOSINE (M(6)A) IS THE MOST THOROUGHLY STUDIED TYPE OF INTERNAL RNA MODIFICATION, AS THIS EPIGENETIC MODIFICATION IS THE MOST ABUNDANT IN EUKARYOTIC RNAS TO DATE. THIS MODIFICATION OCCURS IN VARIOUS TYPES OF RNAS AND PLAYS SIGNIFICANT ROLES IN DOMINANT RNA-RELATED PROCESSES, SUCH AS TRANSLATION, SPLICING, EXPORT AND DEGRADATION. THESE PROCESSES ARE CATALYZED BY THREE TYPES OF PROMINENT ENZYMES: WRITERS, ERASERS AND READERS. INCREASING EVIDENCE HAS SHOWN THAT M(6)A MODIFICATION IS VITAL FOR THE REGULATION OF GENE EXPRESSION, CARCINOGENESIS, TUMOR PROGRESSION AND OTHER ABNORMAL CHANGES, AND RECENT STUDIES HAVE SHOWN THAT M(6)A IS IMPORTANT IN THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA (HCC). HEREIN, WE SUMMARIZE THE NATURE AND REGULATORY MECHANISMS OF M(6)A MODIFICATION, INCLUDING ITS ROLE IN THE PATHOGENESIS OF HCC AND RELATED CHRONIC LIVER DISEASES. WE ALSO HIGHLIGHT THE CLINICAL SIGNIFICANCE AND FUTURE STRATEGIES INVOLVING RNA M(6)A MODIFICATIONS IN HCC. 2021 8 3946 28 LNCRNA MALAT1 BINDS CHROMATIN REMODELING SUBUNIT BRG1 TO EPIGENETICALLY PROMOTE INFLAMMATION-RELATED HEPATOCELLULAR CARCINOMA PROGRESSION. HEPATOCELLULAR CARCINOMA (HCC) IS ONE TYPE OF CANCERS WHOSE CARCINOGENESIS AND PROGRESSION ARE CLOSELY RELATED TO CHRONIC INFLAMMATION. IDENTIFYING THE MOLECULAR MECHANISMS FOR INFLAMMATION-RELATED HCC PROGRESSION WILL CONTRIBUTE TO IMPROVE THE EFFICACY OF CURRENT THERAPEUTICS FOR HCC PATIENTS. MANY KINDS OF EPIGENETIC FACTORS, INCLUDING LONG NON-CODING RNAS (LNCRNAS), HAVE BEEN DISCOVERED TO BE IMPORTANT IN HCC GROWTH AND METASTASIS. HOWEVER, HOW THE LNCRNAS PROMOTE HCC PROGRESSION AND WHAT'S THE APPLICATION OF LNCRNA SILENCING IN VIVO IN SUPPRESSING HCC REMAIN TO BE FURTHER INVESTIGATED. HERE, WE FOUND THAT LNCRNA METASTASIS ASSOCIATED LUNG ADENOCARCINOMA TRANSCRIPT1 (MALAT1) WAS UPREGULATED IN HCC TUMOR TISSUES, AND KNOCKDOWN OF MALAT1 SUPPRESSED PROLIFERATION, CELL CYCLE AND INVASION OF HCC CELLS IN RESPONSE TO LIPOPOLYSACCHARIDE (LPS) STIMULATION. KNOCKDOWN OF MALAT1 SIGNIFICANTLY INHIBITED LPS-INDUCED PRO-INFLAMMATORY MEDIATORS IL-6 AND CXCL8 EXPRESSION IN HCC CELLS, WHICH COULD BE RESTORED BY OVEREXPRESSING MALAT1. MECHANISTICALLY, MALAT1 RECRUITED BRAHMA-RELATED GENE 1 (BRG1), A CATALYTIC SUBUNIT OF CHROMATIN REMODELING COMPLEX SWITCHING/SUCROSE NON-FERMENTABLE (SWI/SNF), TO THE PROMOTER REGION OF IL-6 AND CXCL8, AND THUS FACILITATED NF-KAPPAB TO INDUCE THE EXPRESSION OF THESE INFLAMMATORY FACTORS. IMPORTANTLY, IN VIVO SILENCING OF MALAT1 IN HCC TISSUES INHIBITED GROWTH OF HCC XENOGRAFTS, AND ALSO SUPPRESSED THE EXPRESSION OF PRO-INFLAMMATORY FACTORS IN HCC TISSUES ACCORDINGLY. OUR RESULTS DEMONSTRATE THAT MALAT1 PROMOTES HCC PROGRESSION BY BINDING BRG1 TO EPIGENETICALLY ENHANCE INFLAMMATORY RESPONSE IN HCC TISSUES, AND SILENCING OF MALAT1 MAY BE A POTENTIAL APPROACH TO THE TREATMENT OF HCC. 2019 9 1022 35 CIRCULAR RNA HSA_CIRC_0098181 INHIBITS METASTASIS IN HEPATOCELLULAR CARCINOMA BY ACTIVATING THE HIPPO SIGNALING PATHWAY VIA INTERACTION WITH EEF2. INTRODUCTION AND OBJECTIVES: THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA (HCC) IS A MULTI-STEP PROCESS THAT ACCUMULATES GENETIC AND EPIGENETIC ALTERATIONS, INCLUDING CHANGES IN CIRCULAR RNA (CIRCRNA). THIS STUDY AIMED TO UNDERSTAND THE ALTERATIONS IN CIRCRNA EXPRESSION IN HCC DEVELOPMENT AND METASTASIS AND TO EXPLORE THE BIOLOGICAL FUNCTIONS OF CIRCRNA. MATERIALS AND METHODS: TEN PAIRS OF ADJACENT CHRONIC HEPATITIS TISSUES AND HCC TISSUES FROM PATIENTS WITHOUT VENOUS METASTASES, AND TEN HCC TISSUES FROM PATIENTS WITH VENOUS METASTASES WERE ANALYZED USING HUMAN CIRCRNA MICROARRAYS. DIFFERENTIALLY EXPRESSED CIRCRNAS WERE THEN VALIDATED BY QUANTITATIVE REAL-TIME PCR. IN VITRO AND IN VIVO ASSAYS WERE PERFORMED TO ASSESS THE ROLES OF THE CIRCRNA IN HCC PROGRESSION. RNA PULL-DOWN ASSAY, MASS SPECTROMETRY ANALYSIS, AND RNA-BINDING PROTEIN IMMUNOPRECIPITATION WERE CONDUCTED TO EXPLORE THE PROTEIN PARTNERS OF THE CIRCRNA. RESULTS: CIRCRNA MICROARRAYS REVEALED THAT THE EXPRESSION PATTERNS OF CIRCRNAS ACROSS THE THREE GROUPS WERE SIGNIFICANTLY DIFFERENT. AMONG THESE, HSA_CIRC_0098181 WAS VALIDATED TO BE LOWLY EXPRESSED AND ASSOCIATED WITH POOR PROGNOSIS IN HCC PATIENTS. ECTOPIC EXPRESSION OF HSA_CIRC_0098181 DELAYED HCC METASTASIS IN VITRO AND IN VIVO. MECHANISTICALLY, HSA_CIRC_0098181 SEQUESTERED EUKARYOTIC TRANSLATION ELONGATION FACTOR 2 (EEF2) AND DISSOCIATED EEF2 FROM FILAMENTOUS ACTIN (F-ACTIN) TO PREVENT F-ACTIN FORMATION, WHICH BLOCKED ACTIVATION OF THE HIPPO SIGNALING PATHWAY. IN ADDITION, THE RNA BINDING PROTEIN QUAKING-5 BOUND DIRECTLY TO HSA_CIRC_0098181 AND INDUCED ITS BIOGENESIS. CONCLUSIONS: OUR STUDY REVEALS CHANGES IN CIRCRNA EXPRESSION FROM CHRONIC HEPATITIS, PRIMARY HCC, TO METASTATIC HCC. FURTHER, THE QKI5-HSA_CIRC_0098181-EEF2-HIPPO SIGNALING PATHWAY EXERTS A REGULATORY ROLE IN HCC. 2023 10 5264 26 PROMISING DIRECTIONS IN ATHEROSCLEROSIS TREATMENT BASED ON EPIGENETIC REGULATION USING MICRORNAS AND LONG NONCODING RNAS. ATHEROSCLEROSIS IS ONE OF THE LEADING CAUSES OF MORTALITY FROM CARDIOVASCULAR DISEASE (CVD) AND IS A CHRONIC INFLAMMATORY DISEASE OF THE MIDDLE AND LARGE ARTERIES CAUSED BY A DISRUPTION OF LIPID METABOLISM. NONCODING RNA (NCRNA), INCLUDING MICRORNA (MIRNA), SMALL INTERFERING RNA (SIRNA) AND LONG NONCODING RNA (LNCRNA), WAS INVESTIGATED FOR THE TREATMENT OF ATHEROSCLEROSIS. REGULATION OF THE EXPRESSION OF NONCODING RNA TARGETS THE CONSTITUENT ELEMENT OF THE PATHOGENESIS OF ATHEROSCLEROSIS. CURRENTLY, MIRNA THERAPY COMMONLY EMPLOYS MIRNA ANTAGONISTS AND MIMIC COMPOUNDS. IN THIS REVIEW, ATTENTION IS FOCUSED ON APPROACHES TO CORRECTING MOLECULAR DISORDERS BASED ON THE GENETIC REGULATION OF THE TRANSCRIPTION OF KEY GENES RESPONSIBLE FOR THE DEVELOPMENT OF ATHEROSCLEROSIS. PROMISING TECHNOLOGIES WERE CONSIDERED FOR THE TREATMENT OF ATHEROSCLEROSIS, AND EXAMPLES ARE GIVEN FOR TECHNOLOGIES THAT HAVE BEEN SHOWN TO BE EFFECTIVE IN CLINICAL TRIALS. 2019 11 1021 26 CIRCULAR RNA AS AN EPIGENETIC REGULATOR IN CHRONIC LIVER DISEASES. CIRCULAR RNA (CIRCRNA) IS A TYPE OF NON-CODING RNA CHARACTERIZED BY A COVALENTLY CLOSED CONTINUOUS LOOP. CIRCRNA IS GENERATED BY PRE-MRNA THROUGH BACK-SPLICING AND IS PROBABLY CLEARED UP BY EXTRACELLULAR VESICLES. CIRCRNAS PLAY A PIVOTAL ROLE IN THE EPIGENETIC REGULATION OF GENE EXPRESSION AT TRANSCRIPTIONAL AND POST-TRANSCRIPTIONAL LEVELS. RECENTLY, CIRCRNAS HAVE BEEN DEMONSTRATED TO BE INVOLVED IN THE REGULATION OF LIVER HOMEOSTASIS AND DISEASES. HOWEVER, THE EPIGENETIC ROLE AND UNDERLYING MECHANISMS OF CIRCRNAS IN CHRONIC LIVER DISEASES REMAIN UNCLEAR. THIS REVIEW DISCUSSED THE ROLE OF CIRCRNAS IN NON-NEOPLASTIC CHRONIC LIVER DISEASES, INCLUDING ALCOHOLIC LIVER DISEASE (ALD), METABOLIC-ASSOCIATED FATTY LIVER DISEASE (MAFLD), VIRAL HEPATITIS, LIVER INJURY AND REGENERATION, LIVER CIRRHOSIS, AND AUTOIMMUNE LIVER DISEASE. THE REVIEW ALSO HIGHLIGHTED THAT FURTHER EFFORTS ARE URGENTLY NEEDED TO DEVELOP CIRCRNAS AS NOVEL DIAGNOSTICS AND THERAPEUTICS FOR CHRONIC LIVER DISEASES. 2021 12 2876 28 FUNCTIONAL ROLES OF LONG NONCODING RNA MALAT1 IN GYNECOLOGIC CANCERS. GYNECOLOGIC CANCERS ARE REPRODUCTIVE DISORDERS CHARACTERIZED BY PELVIC PAIN AND INFERTILITY. THE IDENTIFICATION OF NEW PREDICTIVE MARKERS AND THERAPEUTIC TARGETS FOR THE TREATMENT OF GYNECOLOGIC CANCERS IS URGENTLY NECESSARY. ONE OF THE RECENT SUCCESSES IN GYNECOLOGIC CANCERS RESEARCH IS IDENTIFYING THE ROLE OF SIGNALING PATHWAYS IN THE PATHOGENESIS OF THE DISEASE. RECENT EXPERIMENTS SHOWED LONG NONCODING RNAS (LNCRNA) CAN BE NOVEL THERAPEUTIC APPROACHES FOR THE DIAGNOSIS AND TREATMENT OF GYNECOLOGIC CANCERS. LNCRNA ARE TRANSCRIBED RNA MOLECULES THAT PLAY PIVOTAL ROLES IN MULTIPLE BIOLOGICAL PROCESSES BY REGULATING THE DIFFERENT STEPS OF GENE EXPRESSION. METASTASIS-ASSOCIATED LUNG ADENOCARCINOMA TRANSCRIPT-1 (MALAT1) IS A WELL-KNOWN LNCRNA THAT PLAYS FUNCTIONAL ROLES IN GENE EXPRESSION, RNA PROCESSING, AND EPIGENETIC REGULATION. HIGH EXPRESSION OF MALAT1 IS CLOSELY RELATED TO NUMEROUS HUMAN DISEASES. IT IS GENERALLY BELIEVED THAT MALAT1 EXPRESSION IS ASSOCIATED WITH CANCER CELL GROWTH, AUTOPHAGY, INVASION, AND METASTASIS. MALAT1 BY TARGETING MULTIPLE SIGNALING PATHWAYS AND MICRORNAS (MIRNAS) COULD CONTRIBUTE TO THE PATHOGENESIS OF GYNECOLOGIC CANCERS. IN THIS REVIEW, WE WILL SUMMARIZE FUNCTIONAL ROLES OF MALAT1 IN THE MOST COMMON GYNECOLOGIC CANCERS, INCLUDING ENDOMETRIUM, BREAST, OVARY, AND CERVIX. 2023 13 1484 25 DLEU2: A MEANINGFUL LONG NONCODING RNA IN ONCOGENESIS. BACKGROUND: LONG NON-CODING RNA (LNCRNA) WITH LITTLE OR NO CODING ABILITY HAS SHOWN A VARIETY OF BIOLOGICAL FUNCTIONS IN CANCER, INCLUDING EPIGENETIC REGULATION, DNA DAMAGE, REGULATION OF MICRORNAS, AND PARTICIPATION IN SIGNAL TRANSDUCTION PATHWAYS. LNCRNA CAN BE USED AS AN ONCOGENE AND TUMOR SUPPRESSOR GENE THROUGH TRANSCRIPTIONAL REGULATION IN CANCER. FOR EXAMPLE, THE OVER-EXPRESSED LNCRNA DLEU2 PROMOTES THE OCCURRENCE OF LARYNGEAL CANCER, LUNG CANCER, HEPATOCELLULAR CARCINOMA, ETC., AND INHIBITS THE PROGRESSION OF CHRONIC LYMPHOCYTIC LEUKEMIA. DELETED IN LYMPHOCYTIC LEUKEMIA 2 (DLEU2), AS ONE OF THE LONG NON-CODING RNAS, WAS FIRST FOUND IN CHRONIC LYMPHOBLASTIC LEUKEMIA AND DRAWN INTO THE PROGRESS OF INNUMERABLE CANCERS. THE MOLECULAR MECHANISM OF DLEU2 IN MULTIPLE TUMORS WILL BE REVEALED. METHODS: IN THIS REVIEW, CURRENT STUDIES ON THE BIOLOGICAL FUNCTIONS AND MECHANISMS OF DLEU2 IN TUMORS ARE SUMMARIZED AND ANALYZED; RELATED RESEARCHES ARE SYSTEMATICALLY RETRIEVED AND COLLECTED THROUGH PUBMED. RESULTS: DLEU2, A NOVEL CANCER-RELATED LNCRNA, HAS BEEN DEMONSTRATED TO BE ABNORMALLY EXPRESSED IN VARIOUS MALIGNANT TUMORS, INCLUDING LEUKEMIA, ESOPHAGEAL CANCER, LUNG CANCER, GLIOMA, HEPATOCELLULAR CARCINOMA, MALIGNANT PLEURAL MESOTHELIOMA, BLADDER CANCER, PANCREATIC CANCER, PHARYNX AND THROAT CANCER, RENAL CLEAR CELL CARCINOMA, BREAST CANCER, OSTEOSARCOMA. BESIDES, LNCRNA DLEU2 HAS BEEN SHOWN TO BE INVOLVED IN THE PROCESS OF PROLIFERATION, MIGRATION, INVASION AND INHIBITION OF APOPTOSIS OF CANCER CELLS. CONCLUSION: DUE TO THE BIOLOGICAL FUNCTIONS AND MECHANISMS INVOLVED IN DLEU2, IT MAY REPRESENT AN AVAILABLE BIOMARKER OR POTENTIAL THERAPEUTIC TARGET IN A VARIETY OF MALIGNANT TUMORS. 2021 14 6396 38 THE ROLE OF THE MIR-148/-152 FAMILY IN PHYSIOLOGY AND DISEASE. MICRORNAS (MIRNAS) ARE ENDOGENOUSLY ENCODED APPROXIMATELY 22 NT SMALL NON-CODING RNAS. THEY FUNCTION AS KEY PLAYERS OF MANY CELLULAR PROCESSES BY BASE PAIRING WITH TARGET MRNAS AND THEREBY IMPAIRING GENE EXPRESSION AT THE POST-TRANSCRIPTIONAL LEVEL. RECENT FINDINGS DEMONSTRATE A CRITICAL ROLE OF MANY MIRNAS IN IMMUNE CELL DIFFERENTIATION AND IMMUNE RESPONSES, WHICH IS ALSO ASSOCIATED WITH THE DEVELOPMENT AND PROGRESSION OF MANY TUMOR AND NON-TUMOR DISEASES. HERE WE REVIEW THE MULTIFACETED MIRNA-148/-152 FAMILY MEMBERS CONSISTING OF MIR-148A, MIR-148B AND MIR-152. NEXT TO REGULATION MECHANISMS THAT CONTROL THE EXPRESSION OF THIS MIRNA FAMILY, WE WILL FOCUS ON (I) THE ROLE OF MIR-148A IN REGULATING B AND T LYMPHOCYTE FUNCTION AND ITS ROLE IN ASSOCIATED DISEASES AND (II) THE IMPORTANCE OF MIR-148/-152 FAMILY MEMBERS FOR CANCER INITIATION, TUMOR GROWTH AND METASTASIS FORMATION. IN ADDITION, THIS REVIEW AIMS TO HIGHLIGHT SOME SELECTED TARGETS OF THE MIRNA-148/-152 FAMILY MEMBERS, WHICH ARE INVOLVED IN THE BIOLOGY OF CANCER AND MAINTENANCE OF EPIGENETIC PATTERNS. IN CONCLUSION, MEMBERS OF THE MIR-148/-152 FAMILY MIGHT REPRESENT PROGNOSTIC MARKERS AND/OR POTENTIAL THERAPEUTIC TARGETS FOR TREATMENT OF AUTOIMMUNE DISORDERS, CHRONIC INFLAMMATORY DISEASES AND MULTIPLE TYPES OF CANCER. 2017 15 2481 31 EPIGENETIC UPREGULATION OF LNCRNAS AT 13Q14.3 IN LEUKEMIA IS LINKED TO THE IN CIS DOWNREGULATION OF A GENE CLUSTER THAT TARGETS NF-KB. NON-CODING RNAS ARE MUCH MORE COMMON THAN PREVIOUSLY THOUGHT. HOWEVER, FOR THE VAST MAJORITY OF NON-CODING RNAS, THE CELLULAR FUNCTION REMAINS ENIGMATIC. THE TWO LONG NON-CODING RNA (LNCRNA) GENES DLEU1 AND DLEU2 MAP TO A CRITICAL REGION AT CHROMOSOMAL BAND 13Q14.3 THAT IS RECURRENTLY DELETED IN SOLID TUMORS AND HEMATOPOIETIC MALIGNANCIES LIKE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). WHILE NO POINT MUTATIONS HAVE BEEN FOUND IN THE PROTEIN CODING CANDIDATE GENES AT 13Q14.3, THEY ARE DEREGULATED IN MALIGNANT CELLS, SUGGESTING AN EPIGENETIC TUMOR SUPPRESSOR MECHANISM. WE THEREFORE CHARACTERIZED THE EPIGENETIC MAKEUP OF 13Q14.3 IN CLL CELLS AND FOUND HISTONE MODIFICATIONS BY CHROMATIN-IMMUNOPRECIPITATION (CHIP) THAT ARE ASSOCIATED WITH ACTIVATED TRANSCRIPTION AND SIGNIFICANT DNA-DEMETHYLATION AT THE TRANSCRIPTIONAL START SITES OF DLEU1 AND DLEU2 USING 5 DIFFERENT SEMI-QUANTITATIVE AND QUANTITATIVE METHODS (APRIMES, BIOCOBRA, MCIP, MASSARRAY, AND BISULFITE SEQUENCING). THESE EPIGENETIC ABERRATIONS WERE CORRELATED WITH TRANSCRIPTIONAL DEREGULATION OF THE NEIGHBORING CANDIDATE TUMOR SUPPRESSOR GENES, SUGGESTING A COREGULATION IN CIS OF THIS GENE CLUSTER. WE FOUND THAT THE 13Q14.3 GENES IN ADDITION TO THEIR PREVIOUSLY KNOWN FUNCTIONS REGULATE NF-KB ACTIVITY, WHICH WE COULD SHOW AFTER OVEREXPRESSION, SIRNA-MEDIATED KNOCKDOWN, AND DOMINANT-NEGATIVE MUTANT GENES BY USING WESTERN BLOTS WITH PREVIOUSLY UNDESCRIBED ANTIBODIES, BY A CUSTOMIZED ELISA AS WELL AS BY REPORTER ASSAYS. IN ADDITION, WE PERFORMED AN UNBIASED SCREEN OF 810 HUMAN MIRNAS AND IDENTIFIED THE MIR-15/16 FAMILY OF GENES AT 13Q14.3 AS THE STRONGEST INDUCERS OF NF-KB ACTIVITY. IN SUMMARY, THE TUMOR SUPPRESSOR MECHANISM AT 13Q14.3 IS A CLUSTER OF GENES CONTROLLED BY TWO LNCRNA GENES THAT ARE REGULATED BY DNA-METHYLATION AND HISTONE MODIFICATIONS AND WHOSE MEMBERS ALL REGULATE NF-KB. THEREFORE, THE TUMOR SUPPRESSOR MECHANISM IN 13Q14.3 UNDERLINES THE ROLE BOTH OF EPIGENETIC ABERRATIONS AND OF LNCRNA GENES IN HUMAN TUMORIGENESIS AND IS AN EXAMPLE OF COLOCALIZATION OF A FUNCTIONALLY RELATED GENE CLUSTER. 2013 16 2910 34 GENE EXPRESSION PROFILING OF EPIGENETIC CHROMATIN MODIFICATION ENZYMES AND HISTONE MARKS BY CIGARETTE SMOKE: IMPLICATIONS FOR COPD AND LUNG CANCER. CHROMATIN-MODIFYING ENZYMES MEDIATE DNA METHYLATION AND HISTONE MODIFICATIONS ON RECRUITMENT TO SPECIFIC TARGET GENE LOCI IN RESPONSE TO VARIOUS STIMULI. THE KEY ENZYMES THAT REGULATE CHROMATIN ACCESSIBILITY FOR MAINTENANCE OF MODIFICATIONS IN DNA AND HISTONES, AND FOR MODULATION OF GENE EXPRESSION PATTERNS IN RESPONSE TO CIGARETTE SMOKE (CS), ARE NOT KNOWN. WE HYPOTHESIZE THAT CS EXPOSURE ALTERS THE GENE EXPRESSION PATTERNS OF CHROMATIN-MODIFYING ENZYMES, WHICH THEN AFFECTS MULTIPLE DOWNSTREAM PATHWAYS INVOLVED IN THE RESPONSE TO CS. WE HAVE, THEREFORE, ANALYZED CHROMATIN-MODIFYING ENZYME PROFILES AND VALIDATED BY QUANTITATIVE REAL-TIME PCR (QPCR). WE ALSO PERFORMED IMMUNOBLOT ANALYSIS OF TARGETED HISTONE MARKS IN C57BL/6J MICE EXPOSED TO ACUTE AND SUBCHRONIC CS, AND OF LUNGS FROM NONSMOKERS, SMOKERS, AND PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). WE FOUND A SIGNIFICANT INCREASE IN EXPRESSION OF SEVERAL CHROMATIN MODIFICATION ENZYMES, INCLUDING DNA METHYLTRANSFERASES, HISTONE ACETYLTRANSFERASES, HISTONE METHYLTRANSFERASES, AND SET DOMAIN PROTEINS, HISTONE KINASES, AND UBIQUITINASES. OUR QPCR VALIDATION DATA REVEALED A SIGNIFICANT DOWNREGULATION OF DNMT1, DNMT3A, DNMT3B, HDAC2, HDAC4, HAT1, PRMT1, AND AURKB WE IDENTIFIED TARGETED CHROMATIN HISTONE MARKS (H3K56AC AND H4K12AC), WHICH ARE INDUCED BY CS. THUS CS-INDUCED GENOTOXIC STRESS DIFFERENTIALLY AFFECTS THE EXPRESSION OF EPIGENETIC MODULATORS THAT REGULATE TRANSCRIPTION OF TARGET GENES VIA DNA METHYLATION AND SITE-SPECIFIC HISTONE MODIFICATIONS. THIS MAY HAVE IMPLICATIONS IN DEVISING EPIGENETIC-BASED THERAPIES FOR COPD AND LUNG CANCER. 2016 17 5495 29 REVIEW ON CIRCULAR RNAS AND NEW INSIGHTS INTO THEIR ROLES IN CANCER. CIRCULAR RNAS (CIRCRNAS) ARE A VERY INTERESTING CLASS OF CONSERVED SINGLE-STRANDED RNA MOLECULES DERIVED FROM EXONIC OR INTRONIC SEQUENCES BY PRECURSOR MRNA BACK-SPLICING. UNLIKE CANONICAL LINEAR RNAS, CIRCRNAS FORM COVALENTLY CLOSED, CONTINUOUS STABLE LOOPS WITHOUT A 5'END CAP AND 3'END POLY(A) TAIL, AND THEREFORE ARE RESISTANT TO EXONUCLEASE DIGESTION. THE MAJORITY OF CIRCRNAS ARE HIGHLY ABUNDANT, AND CONSERVED ACROSS DIFFERENT SPECIES WITH A TISSUE OR DEVELOPMENTAL-STAGE-SPECIFIC EXPRESSION. CIRCRNAS HAVE BEEN SHOWN TO PLAY IMPORTANT ROLES AS MICRORNA SPONGES, REGULATORS OF GENE SPLICING AND TRANSCRIPTION, RNA-BINDING PROTEIN SPONGES AND PROTEIN/PEPTIDE TRANSLATORS. EMERGING EVIDENCE REVEALS THAT CIRCRNAS FUNCTION IN VARIOUS HUMAN DISEASES, PARTICULARLY CANCERS, AND MAY FUNCTION AS BETTER PREDICTIVE BIOMARKERS AND THERAPEUTIC TARGETS FOR CANCER TREATMENT. IN CONSIDERATION OF THEIR POTENTIAL CLINICAL RELEVANCE, CIRCRNAS HAVE BECOME A NEW RESEARCH HOTSPOT IN THE FIELD OF TUMOR PATHOLOGY. IN THE PRESENT STUDY, THE CURRENT UNDERSTANDING OF THE BIOGENESIS, CHARACTERISTICS, DATABASES, RESEARCH METHODS, BIOLOGICAL FUNCTIONS SUBCELLULAR DISTRIBUTION, EPIGENETIC REGULATION, EXTRACELLULAR TRANSPORT AND DEGRADATION OF CIRCRNAS WAS DISCUSSED. IN PARTICULAR, THE MULTIPLE DATABASES AND METHODS INVOLVED IN CIRCRNA RESEARCH WERE FIRST SUMMARIZED, AND THE RECENT ADVANCES IN DETERMINING THE POTENTIAL ROLES OF CIRCRNAS IN TUMOR GROWTH, MIGRATION AND INVASION, WHICH RENDER CIRCRNAS BETTER PREDICTIVE BIOMARKERS, WERE DESCRIBED. FURTHERMORE, FUTURE PERSPECTIVES FOR THE CLINICAL APPLICATION OF CIRCRNAS IN THE MANAGEMENT OF PATIENTS WITH CANCER WERE PROPOSED, WHICH COULD PROVIDE NEW INSIGHTS INTO CIRCRNAS IN THE FUTURE. 2021 18 3603 30 IMPROPER PREANALYTICAL PROCESSES ON PERIPHERAL BLOOD COMPROMISE RNA QUALITY AND SKEW THE TRANSCRIPTIONAL READOUTS OF MRNA AND LNCRNA. GENETIC AND EPIGENETIC REPROGRAMMING CAUSED BY DISEASE STATES IN OTHER TISSUES IS ALWAYS SYSTEMICALLY REFLECTED IN PERIPHERAL BLOOD LEUKOCYTES (PBLS). ACCURATE TRANSCRIPTIONAL READOUTS OF MESSENGER RNA (MRNA) AND LONG NON-CODING RNA (LNCRNA) IN PERIPHERAL BLOOD LEUKOCYTES ARE FUNDAMENTAL FOR DISEASE-RELATED STUDY, DIAGNOSIS AND TREATMENT. HOWEVER, LITTLE IS KNOWN ABOUT THE IMPACT OF PREANALYTICAL VARIABLES ON RNA QUALITY AND DOWNSTREAM MESSENGER RNA AND LONG NON-CODING RNA READOUTS. IN THIS STUDY, WE EXPLORED THE IMPACT OF RNA EXTRACTION KITS AND TIMING OF BLOOD PLACEMENT ON PERIPHERAL BLOOD LEUKOCYTE-DERIVED RNA QUALITY. A NOVEL ENHANCED EVALUATION SYSTEM INCLUDING RNA YIELDS, PURITY, RNA INTEGRITY NUMBER (RIN) VALUES AND BETA-ACTIN COPIES WAS EMPLOYED TO MORE SENSITIVELY IDENTIFY RNA QUALITY DIFFERENCES. THE EXPRESSION LEVELS OF INFORMATIVE MRNAS AND LONG NON-CODING RNAS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR TRIPLE-NEGATIVE BREAST CANCER (TNBC) WERE MEASURED BY QUANTITATIVE REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (QRT-PCR) TO INVESTIGATE THE IMPACT OF RNA QUALITY ON TRANSCRIPTIONAL READOUTS. OUR RESULTS SHOWED THAT THE QUALITY OF RNA EXTRACTED BY DIFFERENT KITS VARIES GREATLY, AND COMMERCIAL KITS SHOULD BE EVALUATED AND MANAGED BEFORE BATCH RNA EXTRACTION. IN ADDITION, THE QUALITY OF EXTRACTED RNA WAS HIGHLY CORRELATED WITH THE TIMING OF BLOOD PLACEMENT, AND THE COPY NUMBER OF BETA-ACTIN WAS SIGNIFICANTLY DECREASED AFTER LEAVING BLOOD AT RT OVER 12 H. MORE IMPORTANTLY, COMPROMISED RNA LEADS TO SKEWED TRANSCRIPTIONAL READOUTS OF INFORMATIVE MRNAS AND LONG NON-CODING RNAS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE OR TRIPLE-NEGATIVE BREAST CANCER. THESE FINDINGS HAVE SIGNIFICANT IMPLICATIONS FOR PERIPHERAL BLOOD LEUKOCYTE-DERIVED RNA QUALITY MANAGEMENT AND SUGGEST THAT QUALITY CONTROL IS NECESSARY PRIOR TO THE ANALYSIS OF PATIENT MESSENGER RNA AND LONG NON-CODING RNA EXPRESSION. 2022 19 3772 22 INTERACTION BETWEEN MICRORNA AND DNA METHYLATION IN ATHEROSCLEROSIS. ATHEROSCLEROSIS (AS) IS A CHRONIC INFLAMMATORY DISEASE ACCOMPANIED BY COMPLEX PATHOLOGICAL CHANGES, SUCH AS ENDOTHELIAL DYSFUNCTION, FOAM CELL FORMATION, AND VASCULAR SMOOTH MUSCLE CELL PROLIFERATION. MANY APPROACHES, INCLUDING REGULATING AS-RELATED GENE EXPRESSION IN THE TRANSCRIPTIONAL OR POST-TRANSCRIPTIONAL LEVEL, CONTRIBUTE TO ALLEVIATING AS DEVELOPMENT. THE DNA METHYLATION IS A CRUCIAL EPIGENETIC MODIFICATION IN REGULATING CELL FUNCTION BY SILENCING THE RELATIVE GENE EXPRESSION. THE MICRORNA (MIRNA) IS A TYPE OF NONCODING RNA THAT PLAYS AN IMPORTANT ROLE IN GENE POST-TRANSCRIPTIONAL REGULATION AND DISEASE DEVELOPMENT. THE DNA METHYLATION AND THE MIRNA ARE IMPORTANT EPIGENETIC FACTORS IN AS. HOWEVER, RECENT STUDIES HAVE FOUND A MUTUAL REGULATION BETWEEN THESE TWO FACTORS IN AS DEVELOPMENT. IN THIS STUDY, RECENT INSIGHTS INTO THE ROLES OF MIRNA AND DNA METHYLATION AND THEIR INTERACTION IN THE AS PROGRESSION ARE REVIEWED. 2021 20 5981 31 TET2 PROMOTES PATHOGEN INFECTION-INDUCED MYELOPOIESIS THROUGH MRNA OXIDATION. VARIETIES OF RNA MODIFICATION FORM THE EPITRANSCRIPTOME FOR POST-TRANSCRIPTIONAL REGULATION. 5-METHYLCYTOSINE (5-MC) IS A SPARSE RNA MODIFICATION IN MESSENGER RNA (MRNA) UNDER PHYSIOLOGICAL CONDITIONS. THE FUNCTION OF RNA 5-HYDROXYMETHYLCYTOSINE (5-HMC) OXIDIZED BY TEN-ELEVEN TRANSLOCATION (TET) PROTEINS IN DROSOPHILA HAS BEEN REVEALED MORE RECENTLY. HOWEVER, THE TURNOVER AND FUNCTION OF 5-MC IN MAMMALIAN MRNA HAVE BEEN LARGELY UNKNOWN. TET2 SUPPRESSES MYELOID MALIGNANCIES MOSTLY IN AN ENZYMATIC ACTIVITY-DEPENDENT MANNER, AND IS IMPORTANT IN RESOLVING INFLAMMATORY RESPONSE IN AN ENZYMATIC ACTIVITY-INDEPENDENT WAY. MYELOPOIESIS IS A COMMON HOST IMMUNE RESPONSE IN ACUTE AND CHRONIC INFECTIONS; HOWEVER, ITS EPIGENETIC MECHANISM NEEDS TO BE IDENTIFIED. HERE WE DEMONSTRATE THAT TET2 PROMOTES INFECTION-INDUCED MYELOPOIESIS IN AN MRNA OXIDATION-DEPENDENT MANNER THROUGH ADAR1-MEDIATED REPRESSION OF SOCS3 EXPRESSION AT THE POST-TRANSCRIPTION LEVEL. TET2 PROMOTES BOTH ABDOMINAL SEPSIS-INDUCED EMERGENCY MYELOPOIESIS AND PARASITE-INDUCED MAST CELL EXPANSION THROUGH DECREASING MRNA LEVELS OF SOCS3, A KEY NEGATIVE REGULATOR OF THE JAK-STAT PATHWAY THAT IS CRITICAL FOR CYTOKINE-INDUCED MYELOPOIESIS. TET2 REPRESSES SOCS3 EXPRESSION THROUGH ADAR1, WHICH BINDS AND DESTABILIZES SOCS3 MRNA IN A RNA EDITING-INDEPENDENT MANNER. FOR THE UNDERLYING MECHANISM OF TET2 REGULATION AT THE MRNA LEVEL, TET2 MEDIATES OXIDATION OF 5-MC IN MRNA. TET2 DEFICIENCY LEADS TO THE TRANSCRIPTOME-WIDE APPEARANCE OF METHYLATED CYTOSINES, INCLUDING ONES IN THE 3' UNTRANSLATED REGION OF SOCS3, WHICH INFLUENCES DOUBLE-STRANDED RNA FORMATION FOR ADAR1 BINDING, PROBABLY THROUGH CYTOSINE METHYLATION-SPECIFIC READERS, SUCH AS RNA HELICASES. OUR STUDY REVEALS A PREVIOUSLY UNKNOWN REGULATORY ROLE OF TET2 AT THE EPITRANSCRIPTOMIC LEVEL, PROMOTING MYELOPOIESIS DURING INFECTION IN THE MAMMALIAN SYSTEM BY DECREASING 5-MCS IN MRNAS. MOREOVER, THE INHIBITORY FUNCTION OF CYTOSINE METHYLATION ON DOUBLE-STRANDED RNA FORMATION AND ADAR1 BINDING IN MRNA REVEALS ITS NEW PHYSIOLOGICAL ROLE IN THE MAMMALIAN SYSTEM. 2018